佐力藥業(300181.SZ):新開發醫院的數量每年都在增加
格隆匯6月15日丨佐力藥業(300181.SZ)召開線上會議,就“公司是否感受到現在拓展醫院相比於之前更加具有挑戰性和難度?”
公司回覆稱,開發醫院是一個相對複雜的事情,最主要的是產品本身需要滿足進入醫院的所有條件。公司的核心產品烏靈膠囊是國家一類新藥,也是國家醫保產品、國家基本藥物,日均服用價格合理,且在學術端有較強支撐,所以公司如何利用已有的資源去開發醫院非常重要。總體來説,公司在擁有較強優勢的產品的前提下,也有較好的醫院端營銷資源,目前整體的拓展進程還是不錯的,新開發醫院的數量每年都在增加。同時,公司也會利用集採中標的身份,在集采地區加快醫院覆蓋,提高市場佔有率;對已經覆蓋的醫院進行深耕,通過學術推廣等方式慢慢覆蓋更多科室。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.